Close
Nordic 9Nordic 9

Zhejiang Huahai Pharmaceuticals (investor - Corporate Investor)

China
See something wrong or missing? Let us know
Offices:Zhejiang
Average round investment:10M USD
Average number per year:1.0
Distribution: 2023 (1)
Portfolio companies: Finland Aurealis Pharma
Mostly invests in: Finland Finland (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Zhejiang Huahai Pharmaceuticals

Name Criteria
China Lynx Financial
73%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Finland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Finland Ilmarinen
72%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Finland
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
Finland Springvest Oy
71%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Finland
  • Average number of deals per year: 2.1
  • Active last 12 months: Yes
Germany Creathor Venture
71%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Finland
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
Denmark Novo Seeds
71%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Finland
  • Average number of deals per year: 3.3
  • Active last 12 months: Yes
Switzerland Debiopharm Innovation Fund
71%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Finland
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Sweden Bengt Julander
70%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Spain Ekarpen
70%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Peppermint Venture Partners
70%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Riyadh Valley Company
70%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top